OBJECTIVES: To quantify the prevalence of dysplasia and to evaluate the impact of use of cidofovir in recurrent respiratory papilloma biopsy specimens obtained from a pediatric population. DESIGN: Retrospective review of patient medical records and histopathologic test results from January 1, 1998, through December 31, 2008. SETTING: Children's Hospital of Wisconsin. PATIENTS: Patients with a history of operation treated for recurrent respiratory papillomatosis. MAIN OUTCOME MEASURES: The presence or absence of dysplasia identified in a papilloma specimen and patient characteristics, such as age of initial presentation, number of operations, tobacco exposure, treatment for reflux, and use of cidofovir, were quantified. RESULTS: Treatment for recurrent respiratory papillomatosis was identified in 21 patients. Age at initial diagnosis ranged from 8 months to 14 years. A total of 123 recurrent respiratory papillomatosis specimens in 20 patients were identified. Dysplasia was seen in less than 1% of samples (1/123), which represents 5% of total patients. Seven patients (35%) received cidofovir treatment and none of them developed dysplasia. These data demonstrate a lack of correlation between cidofovir treatment and dysplasia, with the P value being nonsignificant (Fisher exact test, P=.4). CONCLUSION: Dysplasia is a rare event in pediatric recurrent respiratory papillomatosis, and there does not appear to be an association between the use of cidofovir and dysplastic changes.
OBJECTIVES: To quantify the prevalence of dysplasia and to evaluate the impact of use of cidofovir in recurrent respiratory papilloma biopsy specimens obtained from a pediatric population. DESIGN: Retrospective review of patient medical records and histopathologic test results from January 1, 1998, through December 31, 2008. SETTING:Children's Hospital of Wisconsin. PATIENTS: Patients with a history of operation treated for recurrent respiratory papillomatosis. MAIN OUTCOME MEASURES: The presence or absence of dysplasia identified in a papilloma specimen and patient characteristics, such as age of initial presentation, number of operations, tobacco exposure, treatment for reflux, and use of cidofovir, were quantified. RESULTS: Treatment for recurrent respiratory papillomatosis was identified in 21 patients. Age at initial diagnosis ranged from 8 months to 14 years. A total of 123 recurrent respiratory papillomatosis specimens in 20 patients were identified. Dysplasia was seen in less than 1% of samples (1/123), which represents 5% of total patients. Seven patients (35%) received cidofovir treatment and none of them developed dysplasia. These data demonstrate a lack of correlation between cidofovir treatment and dysplasia, with the P value being nonsignificant (Fisher exact test, P=.4). CONCLUSION:Dysplasia is a rare event in pediatric recurrent respiratory papillomatosis, and there does not appear to be an association between the use of cidofovir and dysplastic changes.
Authors: R E A Tjon Pian Gi; T Ilmarinen; E R van den Heuvel; L M Aaltonen; J Andersen; J W Brunings; M Chirila; A Dietz; F Ferran Vilà; G Friedrich; H H W de Gier; W Golusinski; M Graupp; A Hantzakos; R Horcasitas; J Jackowska; J C Koelmel; G Lawson; F Lindner; M Remacle; C Sittel; V Weichbold; M Wierzbicka; F G Dikkers Journal: Eur Arch Otorhinolaryngol Date: 2013-02-03 Impact factor: 2.503
Authors: M Fusconi; M Grasso; A Greco; A Gallo; F Campo; M Remacle; R Turchetta; G Pagliuca; M DE Vincentiis Journal: Acta Otorhinolaryngol Ital Date: 2014-12 Impact factor: 2.124